SG10201502566SA - Use of novel pan-cdk inhibitors for treating tumors - Google Patents

Use of novel pan-cdk inhibitors for treating tumors

Info

Publication number
SG10201502566SA
SG10201502566SA SG10201502566SA SG10201502566SA SG10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA
Authority
SG
Singapore
Prior art keywords
treating tumors
cdk inhibitors
novel pan
pan
novel
Prior art date
Application number
SG10201502566SA
Inventor
Ulrich Lücking
Gerhard Siemeister
Antje Margret Wengner
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of SG10201502566SA publication Critical patent/SG10201502566SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
SG10201502566SA 2010-04-01 2011-03-28 Use of novel pan-cdk inhibitors for treating tumors SG10201502566SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010014426A DE102010014426A1 (en) 2010-04-01 2010-04-01 Use of new pan-CDK inhibitors for the treatment of tumors

Publications (1)

Publication Number Publication Date
SG10201502566SA true SG10201502566SA (en) 2015-05-28

Family

ID=43858236

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012065819A SG183925A1 (en) 2010-04-01 2011-03-28 Use of novel pan-cdk inhibitors for treating tumors
SG10201502566SA SG10201502566SA (en) 2010-04-01 2011-03-28 Use of novel pan-cdk inhibitors for treating tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012065819A SG183925A1 (en) 2010-04-01 2011-03-28 Use of novel pan-cdk inhibitors for treating tumors

Country Status (20)

Country Link
US (1) US20130210846A1 (en)
EP (1) EP2552450A1 (en)
JP (1) JP5816259B2 (en)
KR (1) KR20130014678A (en)
CN (1) CN102834100A (en)
AU (1) AU2011234654B2 (en)
BR (1) BR112012024422A2 (en)
CA (1) CA2794996A1 (en)
CL (1) CL2012002753A1 (en)
CR (1) CR20120502A (en)
DE (1) DE102010014426A1 (en)
DO (1) DOP2012000260A (en)
EC (1) ECSP12012198A (en)
MA (1) MA34098B1 (en)
MX (1) MX337722B (en)
NZ (1) NZ602710A (en)
SG (2) SG183925A1 (en)
TN (1) TN2012000469A1 (en)
UA (1) UA108494C2 (en)
WO (1) WO2011120922A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510910A (en) * 2012-03-21 2015-04-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH (RS) -S-cyclopropyl-S- (4-{[4-{[(1R, 2R) -2-hydroxy-1-methylpropyl] oxy} -5- () for the treatment of certain tumors Use of (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) sulfoximide
AU2014224737A1 (en) * 2013-03-07 2015-09-24 Bayer Pharma Aktiengesellschaft Use of (RS)-S-cyclopropyl-S-(4-{(4-{((1R,2R)-2-hydroxy-1-methylpropyl)- oxy}-5-(trifluoromethyl)pyrimidin-2-yl)amino}phenyl)sulfoximide for treatment of specific tumours
NZ711948A (en) * 2013-03-13 2020-02-28 Oncoceutics Inc Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
US20160151370A1 (en) * 2013-06-21 2016-06-02 Bayer Pharma Aktiengesellschaft Substituted Benzylpyrazoles
WO2015071231A1 (en) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Combinations of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating tumours
CN109283263B (en) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 Determination method for Raltitrexed synthesis quality control
CN109283279B (en) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 Pass through high efficiency liquid chromatography for separating and determining Raltitrexed and its method of enantiomter

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (en) 1990-09-19 1992-03-26 Hoechst Ag New 2-aryl:amino-pyrimidine derivs. - contg. alkynyl gp., useful as fungicides
CA2294244A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ATE336484T1 (en) 1998-08-29 2006-09-15 Astrazeneca Ab PYRIMIDINE COMPOUNDS
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
RS94703A (en) 2001-05-29 2007-02-05 Schering Aktiengesellschaft, Cdk inhibiting pyrimidines, production thereof and their use as medicaments
AU2003212282A1 (en) 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
DE10349423A1 (en) * 2003-10-16 2005-06-16 Schering Ag Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments
DE102005062742A1 (en) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag New sulfoximine-substituted pyrimidines useful for treating e.g. diseases caused by inflammatory, allergic or proliferative processes, oncological diseases, cancer, eye, autoimmune and neurodegerative diseases
DE102006027156A1 (en) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag New sulfimide compounds are protein kinase inhibitors useful to treat e.g. cancer, Hodgkin's lymphoma, Kaposi's sarcoma, cardiovascular disease, Crohn's disease, endometriosis and hemangioma
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2179991A1 (en) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine

Also Published As

Publication number Publication date
BR112012024422A2 (en) 2016-05-31
SG183925A1 (en) 2012-10-30
CR20120502A (en) 2012-11-20
JP2013523680A (en) 2013-06-17
MX2012011427A (en) 2013-03-05
AU2011234654A1 (en) 2012-10-25
CL2012002753A1 (en) 2013-01-18
CA2794996A1 (en) 2011-10-06
EP2552450A1 (en) 2013-02-06
TN2012000469A1 (en) 2014-01-30
AU2011234654B2 (en) 2015-08-06
KR20130014678A (en) 2013-02-08
MA34098B1 (en) 2013-03-05
WO2011120922A1 (en) 2011-10-06
MX337722B (en) 2016-03-16
NZ602710A (en) 2014-05-30
UA108494C2 (en) 2015-05-12
US20130210846A1 (en) 2013-08-15
CN102834100A (en) 2012-12-19
DE102010014426A1 (en) 2011-10-06
ECSP12012198A (en) 2012-10-30
DOP2012000260A (en) 2013-03-31
JP5816259B2 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
IL276362A (en) Methods of treating cancer
HK1243919A1 (en) Treatment of cancer with tor kinase inhibitors
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
PL2753334T3 (en) Fap-activated proteasome inhibitors for treating solid tumors
EP2542081A4 (en) Compounds for treatment of cancer
EP2554175A4 (en) Composition for treatment of damaged part
HK1162916A1 (en) Methods of treatment for solid tumors
RS56080B1 (en) Nkcc inhibitors for the treatment of autism
ZA201206456B (en) Uses of dgati inhibitors
EP2643001A4 (en) Method of treating cancer
HK1189272A1 (en) Methods of treating cancer
SG10201502566SA (en) Use of novel pan-cdk inhibitors for treating tumors
EP2544692A4 (en) Use of tigecycline for treatment of cancer
EP2608671A4 (en) Compounds for treatment of cancer
IL221404A (en) Thioxanthone-based autophagy inhibitor for treatment of cancer
EP2640390A4 (en) Methods of treating cancer
EP2897607A4 (en) Inhibitors of beta-hydrolase for treatment of cancer
EP2768512A4 (en) Enzyme inhibitor for cancer treatment
GB201214877D0 (en) Compounds for treatments of tumors
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
IL231448A0 (en) Phosphatidylinositol 3 - kinase inhibitors for the treatment of cancer
GB201019034D0 (en) Treatment for tumors